Skip to main content

Table 1 Demography and clinical characteristics of total cohort and AIT subgroups

From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

 Total cohortPollen SCITPollen SLITHDM SLITP-value
Number of patients249113 (45%)42 (17%)94 (38%) 
Patients withdrawn49 (20%)15 (13%)8 (19%)26 (28%)0.03
Age (years) at which patients started treatment Median (IQR)13 (10–15)15 (12–15)11 (9–14)12 (10–15)< 0.001
Gender
 Male163 (65%)77 (68%)30 (71%)56 (60%)0.3
 Female85 (35%)36 (32%)12 (29%)38 (40%)
Ethnicity
 White European157 (63%)84 (74%)35 (83%)38 (40%)< 0.001
 Other92 (37%)29 (26%)7 (17%)56 (60%)
AR symptoms
 Eyes only14 (6%)4 (4%)7 (17%)3 (3%)0.01b
 Nose only23 (9%)7 (6%)5 (12%)11 (12%)
 Eyes + nose212 (85%)102 (90%)30 (71%)80 (85%)
Allergen sensitisationa
 Grass pollen29 (12%)17 (16%)11 (27%)1 (1%)< 0.001b
 Tree pollen4 (2%)3 (3%)1 (3%)0
 Grass & tree34 (14%)27 (26%)6 (15%)1 (1%)
 HDM23 (10%)1 (1%)022(24%)
 HDM & grass57 (24%)13 (13%)13 (31%)31 (33%)
 HDM & tree4 (2%)004 (4%)
 HDM, grass & tree87 (36%)43 (41%)10 (24%)34 (37%)
Mono-sensitised to AIT
 Yes98 (40%)56 (50%)19 (45%)23 (25%)< 0.001
 No151 (60%)57 (50%)23 (55%)71 (75%)
Medication
 Oral antihistamines5 (2%)2 (2%)1 (2%)2 (2%)0.8b
 OA + adjunct224 (90%)99 (88%)39 (93%)86 (92%)
 Systemics20 (8%)12 (10%)2 (5%)6 (6%)
Other atopic disease
 Asthma101 (41%)51 (45%)13 (31%)37 (39%)0.5
 Eczema21 (8%)10 (9%)2 (5%)9 (10%)
 Asthma + Eczema73 (29%)31 (27%)6 (14%)36 (38%)
Baseline RQLQ
Median (IQR)
65 (38–89)77 (42–98)74 (56–105)57 (28–80)< 0.01
Baseline VAS
Median (IQR)
6 (4–8)7 (5–8)8 (7–9)6 (3–7)< 0.001
  1. AIT allergy immunotherapy, AR allergic rhinoconjunctivitis, HDM house dust mite, IQR interquartile range, OA oral antihistamines, RQLQ rhinoconjunctivitis quality of life questionnaire, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, SPT skin prick test, VAS visual analogue score
  2. P values are between the three treatment groups using Chi squared Test for nominal and Kruskal–Wallis Test for continuous variables. aSensitisation based on SPT or ImmunoCAP bFisher’s Exact test used as data violates conditions for Chi squared Test